Artificial Intelligence for Exosomal Biomarker Discovery for Cardiovascular Diseases: Multi-Omics Integration, Reproducibility, and Translational Prospects

Exosomes and other extracellular vesicles (EVs) carry microRNAs, proteins, and lipids that reflect cardiovascular pathophysiology and can enable minimally invasive biomarker discovery. However, EV datasets are highly dimensional and heterogeneous, strongly influenced by pre-analytic variables and non-standardized isolation/characterization workflows, limiting reproducibility across studies. Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and network-based approaches, can support EV biomarker development by integrating multi-omics profiles with clinical metadata. These approaches enable feature selection, disease subtyping, and interpretable model development. Among the AI approaches evaluated, ensemble methods (Random Forest, gradient boosting) demonstrate the most consistent performance for EV biomarker classification (AUC 0.80-0.92), while graph neural networks (GNNs) are particularly promising for path integration but require larger validation cohorts. Evolutionary neural networks applied to EV morphological features yield comparable discrimination but face interpretability challenges for clinical use. Current studies report promising discrimination performance for selected EV-derived panels in acute myocardial infarction and heart failure. However, most evidence remains exploratory, based on small cohorts (<i>n</i> < 50) and limited external validation. For clinical implementation, EV biomarkers need direct comparison against established standards (high-sensitivity troponin and natriuretic peptides), supported by locked-in assay plans, and validation in multicenter cohorts using MISEV-aligned protocols and transparent AI reporting practices. Through a comprehensive, integrative, and comparative analysis of AI methodologies for EV biomarker discovery, together with explicit criteria for reproducibility and translational readiness, this review establishes a practical framework to advance exosomal diagnostics from exploratory research toward clinical implementation.

Authors

Institutions

Publication Details

Journal
Cells
Published
2026-02-05
DOI
https://doi.org/10.3390/cells15030304
Primary Topic
Extracellular vesicles in disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Artificial Intelligence for Exosomal Biomarker Discovery for Cardiovascular Diseases: Multi-Omics Integration, Reproducibility, and Translational Prospects

Nurittin Ardic, Rasit Dinc
Cells
Extracellular vesicles in disease
article

Artificial Intelligence for Exosomal Biomarker Discovery for Cardiovascular Diseases: Multi-Omics Integration, Reproducibility, and Translational Prospects

Nurittin Ardic, Rasit Dinc
article en

Abstract

Exosomes and other extracellular vesicles (EVs) carry microRNAs, proteins, and lipids that reflect cardiovascular pathophysiology and can enable minimally invasive biomarker discovery. However, EV datasets are highly dimensional and heterogeneous, strongly influenced by pre-analytic variables and non-standardized isolation/characterization workflows, limiting reproducibility across studies. Artificial intelligence (AI), including machine learning (ML), deep learning (DL), and network-based approaches, can support EV biomarker development by integrating multi-omics profiles with clinical metadata. These approaches enable feature selection, disease subtyping, and interpretable model development. Among the AI approaches evaluated, ensemble methods (Random Forest, gradient boosting) demonstrate the most consistent performance for EV biomarker classification (AUC 0.80-0.92), while graph neural networks (GNNs) are particularly promising for path integration but require larger validation cohorts. Evolutionary neural networks applied to EV morphological features yield comparable discrimination but face interpretability challenges for clinical use. Current studies report promising discrimination performance for selected EV-derived panels in acute myocardial infarction and heart failure. However, most evidence remains exploratory, based on small cohorts (<i>n</i> < 50) and limited external validation. For clinical implementation, EV biomarkers need direct comparison against established standards (high-sensitivity troponin and natriuretic peptides), supported by locked-in assay plans, and validation in multicenter cohorts using MISEV-aligned protocols and transparent AI reporting practices. Through a comprehensive, integrative, and comparative analysis of AI methodologies for EV biomarker discovery, together with explicit criteria for reproducibility and translational readiness, this review establishes a practical framework to advance exosomal diagnostics from exploratory research toward clinical implementation.

CellsVol. 15(3)
Environment Agency (GB)
Gender equality
Openalex Percentile: Top 66%
Extracellular vesicles in disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.